Myeloid-derived suppressor cells (MDSCs)
Immature immune cells that tumours summon to switch off T cells. Their numbers in blood predict worse immunotherapy outcomes.
Granulocytic (PMN-MDSC) and monocytic (M-MDSC) subsets; suppress T cells via arginase, iNOS, ROS, and PD-L1. Expanded by G-CSF, IL-6, and VEGF from tumours. Targets under study: CXCR2, STAT3, arginase inhibitors, PI3Kγ; also depleted by some chemotherapies (gemcitabine, 5-FU) and inhibited by PDE5 inhibitors in pilot trials.
Pages like this
not linked directly; found by shared links- TermTumour-associated macrophages (TAMs)
Shares Macrophage, Nutrient competition & metabolic immunosuppression, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Tumour microenvironment (TME).
- TargetCSF1R
Shares The pre-metastatic niche, Nutrient competition & metabolic immunosuppression, Complement in cancer, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals.
- TermImmune exclusion
Shares Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Tumour microenvironment (TME), VEGF / VEGFR.
- TargetCD47
Shares Macrophage, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Tumour microenvironment (TME).
- TargetCXCR4
Shares The pre-metastatic niche, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals.
- PathwayInflammation & NF-κB
Shares JAK–STAT signalling, Complement in cancer, Tumour microenvironment (TME).
- TrialBEATcc / ENGOT-Cx10 / GOG-3030
Shares PD-L1, VEGF / VEGFR.
- TrialIMbrave150
Shares PD-L1, VEGF / VEGFR.